Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.
Full Year revenue increased 12.6% year over year to a record $427.5 millionFull Year net loss of $29.2 million, compared to net loss of $195.5 million in 2024; Non-GAAP adjusted net profit of $13.0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results